Complement Inhibition Promotes Endogenous Neurogenesis and Sustained Anti-Inflammatory Neuroprotection following Reperfused Stroke
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE: The restoration of blood-flow following cerebral ischemia incites a series of deleterious cascades that exacerbate neuronal injury. Pharmacologic inhibition of the C3a-receptor ameliorates cerebral injury by attenuating post-ischemic inflammation. Recent reports also implicate C3a in the modulation of tissue repair, suggesting that complement may influence both injury and recovery at later post-ischemic time-points. METHODS: To evaluate the effect of C3a-receptor antagonism on post-ischemic neurogenesis and neurological outcome in the subacute period of stroke, transient focal cerebral ischemia was induced in adult male C57BL/6 mice treated with multiple regimens of a C3a receptor antagonist (C3aRA). RESULTS: Low-dose C3aRA administration during the acute phase of stroke promotes neuroblast proliferation in the subventricular zone at 7 days. Additionally, the C3a receptor is expressed on T-lymphocytes within the ischemic territory at 7 days, and this cellular infiltrate is abrogated by C3aRA administration. Finally, C3aRA treatment confers robust histologic and functional neuroprotection at this delayed time-point. CONCLUSIONS: Targeted complement inhibition through low-dose antagonism of the C3a receptor promotes post-ischemic neuroblast proliferation in the SVZ. Furthermore, C3aRA administration suppresses T-lymphocyte infiltration and improves delayed functional and histologic outcome following reperfused stroke. Post-ischemic complement activation may be pharmacologically manipulated to yield an effective therapy for stroke.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Others have reported that low-dose treatment with the same C3aR antagonist in an ischemia/reperfusion stroke model in C57BL/6 mice resulted in enhanced neurogenesis, histologic and functional neuroprotection, and an anti-inflammatory effect”
From Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice (2017) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia
Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X. O., Logvinova, A. V., & Greenberg, D. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17977 · Cited by 1,282 · cited 1×
“Alternatively, while an increase in DCX+BrdU+ cells in the hemisphere ipsilateral to an ischemic insult has been described, increased neurogenesis contralateral to an ischemic lesion has also been previously reported [26,27].”
BackgroundComplement regulators and inhibitory proteins
Zipfel, P. F., & Skerka, C. (2009) · Nature Reviews Immunology · doi:10.1038/nri2620 · Cited by 1,264 · cited 1×
“system that plays a critical role in post-ischemic inflammation [1].”
BackgroundVEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia
Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X. O., Logvinova, A., & Greenberg, D. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317977 · Cited by 1,189
Jin, K., Minami, M., Lan, J. Q., Mao, X. O., Batteur, S., Simon, R. P., & Greenberg, D. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081011098 · Cited by 1,051 · cited 1×
“Alternatively, while an increase in DCX+BrdU+ cells in the hemisphere ipsilateral to an ischemic insult has been described, increased neurogenesis contralateral to an ischemic lesion has also been previously reported [26,27].”
BackgroundYamashita, T., Ninomiya, M., Hernandez Acosta, P., Garcia-Verdugo, J. M., Sunabori, T., Sakaguchi, M., Adachi, K., Kojima, T., Hirota, Y., Kawase, T., et al. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0149-06.2006 · Cited by 715 · cited 1×
“This likely relates to our use of a 7-day sacrifice time-point, as the process of neuroblast migration from the SVZ to the ischemic territory and subsequent maturation is not complete by this time [25].”
BackgroundBehavioral Tests After Intracerebral Hemorrhage in the Rat
Hua, Y., Schallert, T., Keep, R. F., Wu, J., Hoff, J. T., & Xi, G. (2002) · Stroke · doi:10.1161/01.str.0000032302.91894.0f · Cited by 509 · cited 1×
“Post-stroke sensorimotor dysfunction was also evaluated using the corner-turn test [21].”
MethodSensorimotor and cognitive deficits after transient middle cerebral artery occlusion in the mouse
Bouët, V., Freret, T., Toutain, J., Divoux, D., Boulouard, M., & Schumann-Bard, P. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.006 · Cited by 302 · cited 1×
“[19], according to the formula: LI = (number of right turnsnumber of left turns)/(total number of turns).”
BackgroundBen-Hur, T., Ben-Menachem, O., Furer, V., Einstein, O., Mizrachi-Kol, R., & Grigoriadis, N. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00218-5 · Cited by 284
Complement: a novel factor in basal and ischemia‐induced neurogenesis
Rahpeymai, Y., Hietala, M. A., Wilhelmsson, U., Fotheringham, A., Davies, I., Nilsson, A., Zwirner, J., Wetsel, R. A., Gerard, C., Pekny, M., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601004 · Cited by 279 · cited 9×
“The high-dose cohort received 20 mg/kg per injection, for a total of 40 mg/kg/day [11].”
BackgroundMethodInfluentialReperfusion Injury after Focal Cerebral Ischemia: The Role Inflammation and the The rapeutic Horizon
Jean, W. C., Spellman, S. R., Nussbaum, E. S., & Low, W. C. (1998) · Neurosurgery · doi:10.1097/00006123-199812000-00076 · Cited by 264
Cited by
Glial Cells: Role of the Immune Response in Ischemic Stroke
Xu, S., Lu, J., Shao, A., Zhang, J. H., & Zhang, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00294 · Cited by 601
“In previous studies, the pharmacological inhibition of the C3a-receptor promoted anti-inflammatory neuroprotection, ameliorated neurological deficits, and improved the outcome after stroke (158, 160).”
BackgroundComplement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice
Shi, Q., Chowdhury, S., Ma, R., Le, K. X., Hong, S., Caldarone, B. J., Stevens, B., & Lemere, C. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6295 · Cited by 593
“Others have reported that low-dose treatment with the same C3aR antagonist in an ischemia/ reperfusion strokemodel in C57BL/6mice resulted in enhanced neurogenesis, histologic and functional neuroprotection, and an antiinflammatory effect (for example, the absence of T lymphocytes expressing C3aRmigrating into the isc…”
BackgroundImmune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke
Endres, M., Moro, M. A., Nolte, C. H., Dames, C., Buckwalter, M. S., & Meisel, A. (2022) · Circulation Research · doi:10.1161/circresaha.121.319994 · Cited by 340
A1/A2 astrocytes in central nervous system injuries and diseases: Angels or devils?
Fan, Y.-Y., & Huo, J. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105080 · Cited by 304
The good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 286
Astrocyte activation and reactive gliosis—A new target in stroke?
Pekny, M., Wilhelmsson, U., Tatlisumak, T., & Pekna, M. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.021 · Cited by 233
Complement peptide C3a stimulates neural plasticity after experimental brain ischaemia
Stokowska, A., Atkins, A. L., Morán, J., Pekny, T., Bulmer, L., Pascoe, M. C., Barnum, S. R., Wetsel, R. A., Nilsson, J. A., Dragunow, M., et al. (2017) · Brain · doi:10.1093/brain/aww314 · Cited by 136
“come following ischaemia-reperfusion in adult mice (Ducruet et al., 2012).”
BackgroundInfluentialSignificance of Complement System in Ischemic Stroke: A Comprehensive Review
Ma, Y., Liu, Y., Zhang, Z., & Yang, G. (2019) · Aging and Disease · doi:10.14336/ad.2019.0119 · Cited by 133
“dose of C3aR antagonist (40 mg/kg) suppressed neural progenitor cell proliferation [414].”
BackgroundThe immune system and stroke: from current targets to future therapy
Malone, K., Amu, S., Moore, A., & Waeber, C. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12191 · Cited by 130
“In a separate study, C3a receptor antagonism suppressed T-cell infiltration, promoted neuroblast formation and provided better histologic and functional outcomes.(24) Inhibition of C5a receptor decreased infarct size and demonstrated an improving trend in neurological function.”
BackgroundComplement in the Homeostatic and Ischemic Brain
Alawieh, A. M., Elvington, A., & Tomlinson, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00417 · Cited by 114
“(73) Ischemic stroke Mouse Transient- MCAO (30 min occlusion time) WT + C3aRA All pathways Acute (45 min before ischemia and then daily) C3aRA treatment (1) increased neurogenesis in a dose-dependent fashion on day 7, (2) reduced T-cell infiltration, (3) reduced infarct volume, mortality and neurological deficit”
BackgroundMethodNew concepts on the therapeutic control of complement anaphylatoxin receptors
Hawksworth, O. A., Li, X. X., Coulthard, L. G., Wolvetang, E. J., & Woodruff, T. M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.05.015 · Cited by 95
“Indeed, in vivo animal studies have shown benefit of C3aR modulation in the treatment brain injury (Rahpeymai et al., 2006; Ducruet et al., 2012; Järlestedt et al., 2013), and of both C3aR and C5aR1 modulation in the control of tumor growth (Corrales et al., 2012; Sayegh et al., 2014; Nabizadeh et…”
BackgroundThe Alternative Complement Pathway Propagates Inflammation and Injury in Murine Ischemic Stroke
Elvington, A., Atkinson, C., Zhu, H., Yu, J., Takahashi, K., Stahl, G. L., Kindy, M. S., & Tomlinson, S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201904 · Cited by 103
“Whereas C1-INH (38) and C3aR antagonist (39) have been shown to be neuroprotective in stroke models, with improved outcome maintained for 7 d after ischemia, lectin pathway deficiency has been shown to provide only acute (24 h) protection after MCAO (40).”
BackgroundAlawieh, A., Elvington, A., Zhu, H., Yu, J., Kindy, M. S., Atkinson, C., & Tomlinson, S. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0464-8 · Cited by 87
“The concept of CR2-fH providing optimal longer-term protection by self-limited complement activation is further supported by findings that high-dose, but not low-dose, C3aR antagonism impaired post-stroke SVZ neurogenesis in the subacute phase [14, 24].”
BackgroundTajiri, N., Kaneko, Y., Shinozuka, K., Ishikawa, H., Yankee, E. W., McGrogan, M. P., Case, C., & Borlongan, C. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074857 · Cited by 94
“Although neurogenic niches in the adult brain, such as the SVZ, have now been documented to exist and demonstrated to be critical in the repair of the stroke brain [43–47], a key limiting factor for endogenous repair is the successful migration of these newly formed host cells to reach the ischemic brain area.”
BackgroundWadhwa, M., Prabhakar, A., Anand, J. P., Ray, K., Prasad, D. N., Kumar, B., & Panjwani, U. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.08.004 · Cited by 82
RetractedImmunomodulatory Therapeutic Strategies in Stroke
Malone, K., Amu, S., Moore, A., & Waeber, C. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00630 · Cited by 76
Stokowska, A., Aswendt, M., Žucha, D., Lohmann, S., Wieters, F., Suarez, J. M., Atkins, A. L., Li, Y., Miteva, M., Lewin, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162253 · Cited by 70
“Systemic pretreatment with a C3aR antagonist reduces granulocyte infiltration and neurological impairment after ischemic stroke (49, 50).”
Stem cell-paved biobridge facilitates neural repair in traumatic brain injury
Tajiri, N., Duncan, K., Antoine, A., Pabon, M. M., Acosta, S. A., de la Peña, I., Hernandez‐Ontiveros, D. G., Shinozuka, K., Ishikawa, H., Kaneko, Y., et al. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00116 · Cited by 64
“…and DCX) migrating not only along but also across the CC from the SVZ to the impacted CTX. Contrastingly, TBI rats which received vehicle infusion exhibited elevated cellular proliferation; however the newly formed cells were “trapped” within the SVZ and CTX and did not migrate to the impacted CTX.”
BackgroundInflammation and the Link to Vascular Brain Health: Timing Is Brain
Mun, K. T., & Hinman, J. D. (2022) · Stroke · doi:10.1161/strokeaha.121.032613 · Cited by 65
Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke
Liu, C., Xie, J., Sun, S., Li, H., Li, T., Jiang, C. Q., Chen, X., Wang, J., Le, A., Wang, J., et al. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00985-1 · Cited by 63
Yang, J., Ahn, H., Chang, M., Narasimhan, P., Chan, P. H., & Song, Y. S. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12111 · Cited by 59
Complement activation in the context of stem cells and tissue repair
Schraufstätter, I. U., Khaldoyanidi, S. K., & DiScipio, R. G. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i8.1090 · Cited by 67
Complement cascade functions during brain development and neurodegeneration
Fatoba, O., Itokazu, T., & Yamashita, T. (2021) · FEBS Journal · doi:10.1111/febs.15772 · Cited by 61
Aberrant Complement System Activation in Neurological Disorders
Ziąbska, K., Ziemka‐Nałęcz, M., Pawelec, P., Sypecka, J., & Zalewska, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094675 · Cited by 56
Receptor for complement peptide C3a: a therapeutic target for neonatal hypoxic‐ischemic brain injury
Järlestedt, K., Rousset, C. I., Ståhlberg, A., Šourková, H., Atkins, A. L., Thornton, C., Barnum, S. R., Wetsel, R. A., Dragunow, M., Pekny, M., et al. (2013) · The FASEB Journal · doi:10.1096/fj.13-230011 · Cited by 53
“This work was supported by the Swedish Research Council (20116, 14185, 11548, 2642, 2367); ALF Gothenburg (11267, 142821, 146051, 2863); the Stena Foundation; The Magnus Bergvall Foundation; the W. and M. Lundgren Foundation; The Free Mason Foundation; The Åhlén Foundation; Wellcome Trust; AFA Insurance; EU projects N…”
BackgroundMethodInfluentialComplement After Trauma: Suturing Innate and Adaptive Immunity
Chakraborty, S., Karasu, E., & Huber-Lang, M. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02050 · Cited by 50
“In post reperfused stroke it was seen that treatment with C3aR antagonist diminished infiltration of C3aR-expressing T-cells at the ischemic site, helping in neurogenesis (43).”
BackgroundAhmad, S., Khan, S. A., Kindelin, A., Mohseni, T., Bhatia, K., Hoda, M. N., & Ducruet, A. F. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08569-z · Cited by 47
Self-citationWeissleder, C., North, H. F., Bitar, M., Fullerton, J. M., Sager, R., Barry, G., Piper, M., Halliday, G. M., Webster, M. J., & Weickert, C. S. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01149-3 · Cited by 50
Complement Peptide C3a Promotes Astrocyte Survival in Response to Ischemic Stress
Shinjyo, N., de Pablo, Y., Pekny, M., & Pekna, M. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9204-4 · Cited by 49
“Based on the effects of a low-dose C3aR antagonist treatment, Connely and co-workers concluded that C3aR inhibition attenuates brain injury after cerebral hemorrhage and ischemia/ reperfusion via reducing granulocyte infiltration [49, 50], as well as suppression of T-lymphocyte infiltration and stimulation of neurobla…”
BackgroundEndogenous neurogenesis following ischaemic brain injury: Insights for therapeutic strategies
Merson, T. D., & Bourne, J. A. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.08.003 · Cited by 43
Sigfridsson, E., Marangoni, M., Johnson, J. A., Hardingham, G. E., Fowler, J. H., & Horsburgh, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-30675-4 · Cited by 41
Targeting Complement C3a Receptor to Improve Outcome After Ischemic Brain Injury
Pekna, M., Stokowska, A., & Pekny, M. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03419-6 · Cited by 41
Passarelli, J. P., Nimjee, S. M., & Townsend, K. L. (2022) · Translational Stroke Research · doi:10.1007/s12975-022-01109-1 · Cited by 44
Tang, J., Jila, S., Luo, T., Zhang, B., Miao, H., Feng, H., Chen, Z., & Zhu, G. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108927 · Cited by 39
Tissue plasminogen activator mediates deleterious complement cascade activation in stroke
Zhao, X.-J., Larkin, T. M., Lauver, M. A., Ahmad, S., & Ducruet, A. F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180822 · Cited by 37
“The present study also confirms the neuroprotective effect of complement inhibition in stroke and represents the first effort to evaluate the functional effects of complement inhibition following tPA administration [1, 2, 5, 13, 15, 33].”
BackgroundMethodResultSelf-citationLi, T., Pan, Y.-W., Wang, W., Abel, G. M., Zou, J., Xu, L., Storm, D. R., & Xia, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061948 · Cited by 40
“The density of BrdU cells, BrdU and NeuN co-labeled cells, and YFP cells in the OB were quantified using the Optical Fractionator Probe of Stereology Investigator Software (MBF Bioscience), a wellestablished method to quantify cell numbers without bias [28,29,30].”
MethodBoswellic acids as promising agents for the management of brain diseases
Rajabian, A., Farzanehfar, M., Hosseini, H., Arab, F. L., & Nikkhah, A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121196 · Cited by 36
Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics
Gavriilaki, M., Kimiskidis, V. Κ., & Gavriilaki, E. (2020) · Pharmaceuticals · doi:10.3390/ph13110341 · Cited by 33
Ahmad, S., Kindelin, A., Khan, S. A., Ahmed, M., Hoda, M. N., Bhatia, K., & Ducruet, A. F. (2019) · Experimental Neurobiology · doi:10.5607/en.2019.28.2.216 · Cited by 31
Self-citationComplement in stem cells and development
Hawksworth, O. A., Coulthard, L. G., Mantovani, S., & Woodruff, T. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.009 · Cited by 34
Liu, Q., He, S., Groysman, L. I., Shaked, D., Russin, J. J., Cen, S., & Mack, W. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084802 · Cited by 33
“Through the broad proinflammatory actions of the anaphylotoxins, complement upregulation is associated with cellular injury in the setting of stroke and neurodegenerative disease[24].”
BackgroundTherapeutic Modulation of the Complement Cascade in Stroke
Clarke, A. R., Christophe, B. R., Khahera, A. S., Sim, J., & Connolly, E. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01723 · Cited by 30
“Similarly, C3aRA treatment early following stroke not only protected mice but enhanced delayed, post-stroke neurogenesis (50, 52).”
BackgroundSelf-citationZhang, J., Zhou, R., Cao, G., Zhang, Y., Xu, H., & Yang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.818245 · Cited by 32
“As the ligand of C5AR1, C5a is a member of the complement system and exhibits multiple inflammatory activities, such as stimulating cells to secret inflammatory factors or recruiting and activating leukocytes (Ducruet et al., 2012).”
BackgroundStem Cell-Induced Biobridges as Possible Tools to Aid Neuroreconstruction after CNS Injury
Lee, J.-Y., Xu, K., Nguyen, H., Guedes, V. A., Borlongan, C. V., & Acosta, S. A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00051 · Cited by 28
“…such as the SVZ, that mobilize endogenous cells to repair the stroke brain, a major limiting factor for endogenous repair is the absence of effective cellular migration to the area of injury (Ekdahl et al., 2009; Ducruet et al., 2012; Hassani et al., 2012; Wang et al., 2012; Trueman et al., 2013).”
BackgroundAhmad, S., Pandya, C. D., Kindelin, A., Bhatia, K., Chaudhary, R., Dwivedi, A. K., Eschbacher, J. M., Liu, Q., Waters, M. F., Hoda, M. N., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14989 · Cited by 24
“We have extensively reported that C3a/C3a receptor axis is integral to the pathophysiology of ischaemic stroke independent of the stroke subtype and pattern of reperfusion (Ducruet et al., 2008; Ducruet et al., 2009; Ducruet et al., 2012).”
BackgroundSelf-citationMou, T.-C. M., Lane, M. V., Ireland, D. D. C., Verthelyi, D. I., Tonelli, L. H., & Clark, S. M. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105840 · Cited by 27
“(Ducruet et al., 2012; Moriyama et al., 2011), possibly by reducing elimination of immature cells.”
BackgroundWu, H., Yang, S., Dai, J., Qiu, Y., Miao, Y., & Zhang, X. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4327 · Cited by 22
“Previous studies have aimed to overcome this limitation by developing methods that induce, mimic or enhance endogenous protective responses, and do not interfere with physiological neurotransmission (18-20).”
The Role of Complement C3a Receptor in Stroke
Ahmad, S., Bhatia, K., Kindelin, A., & Ducruet, A. F. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08545-7 · Cited by 21
Self-citationPost-stroke depression and the aging brain
Cojocaru, G. R., Popa‐Wagner, A., Stănciulescu, E. C., Babadan, L., & Buga, A.-M. (2013) · Journal of Molecular Psychiatry · doi:10.1186/2049-9256-1-14 · Cited by 23
“In addition, two new genes, complement component 3 and fatty acid-binding protein 7, have recently been described [80,81].”
BackgroundZhang, B., Yang, N., & Gao, C. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1100-7 · Cited by 19
“The alternative pathway only conducted by C3 plays an important role in driving inflammation and propagating injury in many neuroinflammatory conditions such as traumatic spinal cord injury [21] and traumatic brain injury [22], moreover, animal studies had also confirmed that the alternative complement pathway receive…”
BackgroundNeuroimmunological effects of early life experiences
Brydges, N. M., & Reddaway, J. (2020) · Brain and Neuroscience Advances · doi:10.1177/2398212820953706 · Cited by 22
“Complement receptor 2 (CR2) agonism inhibits neuronal proliferation, whereas antagonism of complement component 3a receptor (C3aR) promotes proliferation (Ducruet et al., 2012; Moriyama et al., 2011).”
BackgroundInhibition of C5aR1 as a promising approach to treat taxane-induced neuropathy
Cristiano, C., Giorgio, C., Cocchiaro, P., Boccella, S., Cesta, M. C., Castelli, V., Liguori, F. M., Cuozzo, M., Brandolini, L., Russo, R., et al. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156370 · Cited by 17
Bhatia, K., Kindelin, A., Nadeem, M., Khan, M. B., Yin, J., Fuentes, A. E., Miller, K., Turner, G. H., Preul, M. C., Ahmad, A. S., et al. (2022) · Translational Stroke Research · doi:10.1007/s12975-022-00993-x · Cited by 19
“is limited in its ability to specifically target C3aR due to concentration dependence and cell-specific effects [33, 58].”
BackgroundSelf-citationAkhter, N., Lambay, A., Almotairi, R., Hamadi, A., Bhatia, K., Ahmad, S., & Ducruet, A. F. (2025) · Cells · doi:10.3390/cells14181440 · Cited by 14
“These approaches elevate the levels of complement components (C1q, C3a, C5a) in the brain [24,60–62], C1q in microglia [63], and C5 in neurons [61].”
InfluentialSelf-citationReddaway, J., & Brydges, N. M. (2020) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103567 · Cited by 17
“complement component C3a receptor 1 (C3aR1), promotes neuroblast proliferation (Ducruet et al., 2012; Moriyama et al., 2011).”
BackgroundGibson, B. G., Cox, T. E., & Marchbank, K. J. (2022) · Immunological Reviews · doi:10.1111/imr.13141 · Cited by 14
Paredes, R. M., Reyna, S. L., Vernon, P. J., Tadaki, D. K., Dallelucca, J. J., & Sheppard, F. R. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.10.033 · Cited by 12
“C3 deficiency or inhibition has been shown to provide a protective effect in the acute phase following ischemic stroke [9,10], but prolonged C3 deficiency can lead to infection and worse long term outcomes [11].”
BackgroundInfluentialComplement C3a: Shaping the Plasticity of the Post-stroke Brain
Stokowska, A., & Pekna, M. (2017) · Springer series in translational stroke research · doi:10.1007/978-3-319-66679-2_26 · Cited by 14
Complement C3 activation in the ICU: Disease and therapy as Bonnie and Clyde
Mannes, M., Mastellos, D. C., Ekdahl, K. N., Nilsson, B., Yancopoulou, D., Lambris, J. D., & Huber-Lang, M. S. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101640 · Cited by 11
Li, X., Pan, M., Tian, X., Yang, L., Zhang, J., Yan, D., Xu, B., Zhao, L., & Fang, W. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s469651 · Cited by 10
“13,17 In addition to the complement intrinsic components and complement receptors, complement regulatory proteins are important components of the complement system.”
BackgroundA NEW METHOD TO ASSESS FUNCTIONAL ACTIVITY OF SERUM COMPLEMENT SYSTEM
Черемных, Е. Г., Ivanov, P. A., Mi, F., Karpova, N. S., Vasilyeva, E. F., Gusev, K. V., & Os, B. (2015) · Medical Immunology (Russia) · doi:10.15789/1563-0625-2015-5-479-488 · Cited by 6
Zhang, X., Li, C., Wang, Y., Liu, Y., Han, Y., Jing, Y., & Deng, F. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13783-4 · Cited by 3
Puglisi, C. H., Ander, B. P., Peterson, C., Keiter, J. A., Hull, H., Hawk, C. W., Kalistratova, V. S., Izadi, A., Gurkoff, G. G., Sharp, F. R., et al. (2022) · Translational Stroke Research · doi:10.1007/s12975-022-01061-0 · Cited by 5
“C3 receptors may be blocked with C3a receptor antagonist SB290157 which has been found to improve outcomes after ischemia [42].”
BackgroundMaino, B., Spampinato, A. G., Severini, C., Petrella, C., Ciotti, M. T., D’Agata, V., Calissano, P., & Cavallaro, S. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26744 · Cited by 3
The Complement Cascade in Acute Brain Injury
McDowell, M. M., Shea, N. J., Gupta, G., & Connolly, E. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8915-3_5 · Cited by 1
Self-citation(2014) · Inflammation and Cell Signaling · doi:10.14800/ics.82 · Cited by 1
“A number of animal and human studies ([29-39]), including our own ([40-42]), demonstrated that activation of the complement system play a decisive role in the pathophysiology of IS.”
BackgroundChen, H., Frank, J. A., Tan, C., Lee, A. G., Kopchock, R., Chiang, T., Kim, A. Y., Galvan, M. D., Fraser, J. F., Dornbos, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.26.661858 · Cited by 1
TREM-2 expression and regulation in inflammation and ischaemia
Bradley, J. (2014) · UEA Digital Repository (University of East Anglia)
From Neurogenic Niche to Site of Injury: Stem Cell-Mediated Biobridge for Brain Repair
de la Peña, I., Tajiri, N., Acosta, S., Reyes, S., Yoo, A., McGrogan, M. P., Aizman, I., Yankee, E. W., Bates, D., & Borlongan, C. V. (2015) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-21702-4_7
The Role of Immune Mechanism in the Process of Secondary Brain Injury
黄, 德. (2014) · Advances in Clinical Medicine · doi:10.12677/acm.2014.42004
Adult Neurogenesis in Health and Disease
Mobley, A. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-811014-0.00008-1
Complementing Subarachnoid Hemorrhage
van Dijk, B. J. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/210
Inhibition of the complement anaphylatoxin activities in the central nervous system disorders
Nekrasova, K. A., Ischenko, A. M., & Trofimov, A. V. (2021) · Medical academic journal · doi:10.17816/maj71315
Vasanth, S., Ghosh, S., & Chakravarty, S. (2025) · Neuroscience Insights Advances in Brain Studies · doi:10.64978/niabs-0101
THE MICROANATOMY OF INTRACRANIAL HUMAN THROMBI BY SINGLE NUCLEI TRANSCRIPTOMICSPreprint
Leifer, V. P., Argenziano, M., Sperring, C. P., Zhao, W., Alexander, J. E., Mahajan, A., Furnari, J. L., Kotidis, C. P., Mandigo, G. K., Canoll, P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.29.755188
“Therapeutic targeting of mechanisms involved in impaired microvascular reperfusion has been shown to be neuroprotective in animal models [4], [5], [6], [7], [8], [9].”
Self-citation
Metadata
- Authors
- Ducruet, A. F., Zacharia, B. E., Sosunov, S. A., Gigante, P. R., Yeh, M. L., Gorski, J. W., Otten, M. L., Hwang, R. Y., DeRosa, P. A., Hickman, Z. L., Sergot, P., & Connolly, E. S.
- Affiliations
- Columbia University (US)
- Corresponding author
- Ducruet, Andrew F.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-06-26
- Volume
- 7
- Issue
- 6
- Pages
- e38664
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3383680
- OpenAlex
- W2058792228
- Cited by
- 75
- References
- 35
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 10 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 6 · 2017: 6 · 2016: 1 · 2015: 8 · 2014: 7 · 2013: 6 · 2012: 2
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- American Heart Association
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS040409)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- complement inhibition, cerebral ischemia, endogenous neurogenesis, subventricular zone, T cell infiltration, post-ischemic inflammation, neuroblast proliferation, stroke treatment
- MeSH terms
- Animals, Anti-Inflammatory Agents, Brain Ischemia, Disease Models, Animal, Inflammation, Male, Mice, Inbred C57BL, Receptors, Complement, T-Lymphocytes, Reperfusion Injury, Complement C3a, Survival Rate, Neuroprotective Agents, Stroke, Mice, Neurogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.